Back to Search
Start Over
Autologous haematopoietic stem cell transplantation and other cellular therapy in multiple sclerosis and immune-mediated neurological diseases
- Source :
- Bone Marrow Transplantation, 55(2), 283. Nature Publishing Group, Dipòsit Digital de Documents de la UAB, Universitat Autònoma de Barcelona, Recercat. Dipósit de la Recerca de Catalunya, instname, Bone Marrow Transplantation, Recercat: Dipósit de la Recerca de Catalunya, Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya), Bone Marrow Transplantation, 55(2), 283-306. NATURE PUBLISHING GROUP
- Publication Year :
- 2020
- Publisher :
- NATURE PUBLISHING GROUP, 2020.
-
Abstract
- These updated EBMT guidelines review the clinical evidence, registry activity and mechanisms of action of haematopoietic stem cell transplantation (HSCT) in multiple sclerosis (MS) and other immune-mediated neurological diseases and provide recommendations for patient selection, transplant technique, follow-up and future development. The major focus is on autologous HSCT (aHSCT), used in MS for over two decades and currently the fastest growing indication for this treatment in Europe, with increasing evidence to support its use in highly active relapsing remitting MS failing to respond to disease modifying therapies. aHSCT may have a potential role in the treatment of the progressive forms of MS with a significant inflammatory component and other immune-mediated neurological diseases, including chronic inflammatory demyelinating polyneuropathy, neuromyelitis optica, myasthenia gravis and stiff person syndrome. Allogeneic HSCT should only be considered where potential risks are justified. Compared with other immunomodulatory treatments, HSCT is associated with greater short-term risks and requires close interspeciality collaboration between transplant physicians and neurologists with a special interest in these neurological conditions before, during and after treatment in accredited HSCT centres. Other experimental cell therapies are developmental for these diseases and patients should only be treated on clinical trials.
- Subjects :
- Feature
medicine.medical_specialty
Multiple Sclerosis
Neurologi
Bone marrow transplantation
2747 Transplantation
medicine.medical_treatment
Immunology
2720 Hematology
Chronic inflammatory demyelinating polyneuropathy
610 Medicine & health
Disease
Hematopoietic stem cell transplantation
Transplantation, Autologous
Accreditation
Autoimmune Diseases
03 medical and health sciences
0302 clinical medicine
Internal medicine
medicine
Humans
European Society for Blood and Marrow Transplantation (EBMT) Autoimmune Diseases Working Party (ADWP) and the Joint Accreditation Committee of the International Society for Cellular Therapy (ISCT) and EBMT (JACIE)
Intensive care medicine
Peripheral neuropathies
Transplantation
Hematology
Neuromyelitis optica
business.industry
Multiple sclerosis
Hematopoietic Stem Cell Transplantation
1103 Clinical Sciences
medicine.disease
10040 Clinic for Neurology
Clinical trial
Europe
surgical procedures, operative
Neurology
business
030217 neurology & neurosurgery
030215 immunology
Subjects
Details
- Language :
- English
- ISSN :
- 02683369
- Database :
- OpenAIRE
- Journal :
- Bone Marrow Transplantation, 55(2), 283. Nature Publishing Group, Dipòsit Digital de Documents de la UAB, Universitat Autònoma de Barcelona, Recercat. Dipósit de la Recerca de Catalunya, instname, Bone Marrow Transplantation, Recercat: Dipósit de la Recerca de Catalunya, Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya), Bone Marrow Transplantation, 55(2), 283-306. NATURE PUBLISHING GROUP
- Accession number :
- edsair.doi.dedup.....4de3e8dad1e880bd01bd48db1d923112